Gentian’s PETIA technology offers the benefits of cost-effective open platform testing, with shorter time-to-result and higher throughput compared to other immunoassay systems, perfectly responding to the increasing needs for SARS-CoV-2 antibody testing.
"Many IVD companies have already established COVID-19 antibody tests, however, these tests use assay technologies which usually result in a lower volume throughput. The Gentian antibody test will be a turbidimetric COVID-19 assay using the PETIA technology. The PETIA technology offers the benefits of cost-effective open platform testing, with shorter time-to-result and higher throughput compared to other immunoassay systems, perfectly responding to the envisaged testing needs for COVID-19"
Torsten Knüttel, VP R&D, Gentian
PETIA COVID-19/SARS-CoV-2 antibody test in development
Gentian has, over the last few months, worked in close cooperation with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway.
Through this cooperation, we have completed some explorative test work that supports the concept of developing a turbidimetric SARS-CoV-2 antibody test based on Gentian’s proprietary technology. The immunoassay, if successfully developed, will be designed for use on high-throughput clinical chemistry analysers that are available in major laboratories around the world.
The project is now in the proof-of-concept phase, with a strong focus on technical feasibility and market assessment to further specify the project and assay development. Subject to fulfillment of the criteria for this phase, the project intention is to undertake a fast track development with a planned launch in 2021.